Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

ConditionsEGFR Mutation Positive Non-small Cell Lung Cancer EGFR Mutated Non-small Cell Lung Cancer Patients

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorNuvectis Pharma, Inc.

About this trial

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Eligibility criteria

Qualifiers

Provide written informed consent.

18 years old or older.

Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.

Disqualifiers

Subject's cancer has a known oncogenic driver alteration other than EGFR.

Known EGFR mutations that cause resistance to osimertinib

Known human epidermal growth factor receptor 2 (HER2) overexpression

Any contraindications to treatment with osimertinib

Trial design

Treatments tested in this trial

NXP900
Osimertinib

Treatment groups

18 Participants

are divided into 1 treatment group

Sponsors and collaborators

Nuvectis Pharma, Inc.

Lead sponsor

Source ClinicalTrials.gov